Business

Piper Sandler starts Benitec at overweight, cites BB-301 opportunity (NASDAQ:BNTC)

IvelinRadkov

Piper Sandler initiated coverage of Benitec Biopharma (NASDAQ:BNTC) with an overweight rating, stating it believes the therapy BB-301 has a strong probability of success in the treatment of oculopharyngeal muscular dystrophy, or OPMD.

The investment bank said it believes “strong first patient


Source link

Related Articles

Back to top button